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Abstract
Hepatocellular carcinoma (HCC) is the predominant 
form of primary liver cancer and represents the third 
leading cause of cancer-related death worldwide. 
Current available therapeutic approaches are poorly 
effective, especially for the advanced forms of the 
disease. In the last year, short double stranded RNA 
molecules termed small interfering RNAs (siRNAs) and 
micro interfering RNAs (miRNA), emerged as interesting 
molecules with potential therapeutic value for HCC. 
The practical use of these molecules is however limited 
by the identification of optimal molecular targets and 
especially by the lack of effective and targeted HCC 
delivery systems. Here we focus our discussion on the 
most recent advances in the identification of siRNAs/
miRNAs molecular targets and on the development of 
suitable siRNA/miRNAs delivery systems.
Key words: Small interfering RNA; Micro interfering 
RNA; Delivery; Hepatocellular carcinoma; Therapeutic 
potential
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Core tip: Available therapeutic approaches for 
hepatocellular carcinoma (HCC) are poorly effective, 
especially for the advanced forms of the disease. In the 
last year, short double stranded RNA molecules termed 
small interfering RNAs (siRNAs) and micro interfering 
RNAs (miRNA), emerged as interesting molecules with 
potential therapeutic value for HCC. The practical use of 
and miRNAs targeted against any cellular RNA, 
these molecules can be used to down regulate the 
expression of virtually any gene causing disease. This 
explains the great therapeutic potential, well witnessed 
by the numerous papers so far published[7,9-15].
Obstacles to the use of miRNAs/siRNAs
Despite the great therapeutic value, for the practical 
use of miRNAs/siRNAs two orders of problems need 
to be addressed. The first is represented by the off 
targeting effect and the second deals with the effective 
delivery.
The off targeting effect[8] can be defined as the 
possibility of miRNAs/siRNAs to interact, in addition 
to the target RNA, also with other RNAs. This 
phenomenon is based on an imperfect hybridization 
between the miRNA/siRNA antisense strand and 
RNAs different from the target. This can lead to the 
unwanted silencing of genes resulting in unpredictable 
effects in the diseased tissue and, more importantly, 
in the healthy one. To minimize the side effects, 
different strategies have been developed. Among 
these, applicable solutions are the scale down of 
miRNA/siRNA concentration, the chemical modification 
and the careful choice of the sequences[8].
The delivery issue deals with the fact that following 
systemic administration, siRNAs/miRNAs (Figure 1) 
can be rapidly degraded by extracellular nucleases, 
can be eliminated by the reticulo-endothelial system/
kidney filtration[16] and may activate the immune 
system[17,18]. Moreover, being negatively charged 
hydrophilic molecules, siRNAs/miRNAs are repulsed by 
the negatively charged surface of the cell membrane 
and by its hydrophobic layer. Notably, following cellular 
uptake, siRNAs/miRNAs can be sequestered into 
endosomes with no possibility to reach the target RNA 
into the cytoplasm/nucleus. Finally, a targeting strategy 
to the diseased tissue is utmost desirable to minimize/
abolish side effects stemming from the targeting of 
the healthy tissue (Figure 1). So far, delivery systems 
based on the use of viral vectors or synthetic vectors 
have been developed. Here we will briefly discuss the 
most recent news about the development of synthetic 
vectors.
THERAPEUTIC POTENTIAL OF MIRNA/
SIRNA FOR HCC
Despite the above mentioned problems, active 
investigations are in progress for: (1) the identification 
of suitable anti HCC target for siRNA/miRNAs; and (2) 
the development of effective and targeted delivery 
systems for siRNA/miRNAs to the liver. Among the 
several works reported in the past[19], in the following 
sections, we have reported some of the most 
notable and recent examples of works aimed at the 
identification of molecular HCC targets and delivery 
systems based on the use of miRNAs/siRNAs. 
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INTRODUCTION
Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC), the predominant 
form of primary liver cancer, is the third leading cause 
of cancer-related death worldwide[1-3]. While HCC 
is most common in Asia and Africa, its incidence in 
the western countries is increasing. As usually HCC 
diagnosis occurs in the advanced stage of the disease, 
available treatments such as resection, liver transplant, 
or local ablation are poorly if not at all effective. Also 
systemic chemotherapy has limited effectiveness due 
to general HCC resistance to anticancer agents[4]. The 
only drug that can significantly prolong patient survival 
is Sorafenib[5]; unfortunately, however, the extent of 
increased survival is very modest being of few months. 
Together the above considerations clearly indicate 
that the development of novel therapeutic approaches 
for HCC are urgently necessary. In this regard, small 
interfering RNAs (siRNAs) and micro-interfering RNAs 
(miRNAs), belonging to the big family of nucleic acid 
based drugs[6,7], are emerging as attractive therapeutic 
molecules.
MiRNAs/siRNAs
MiRNAs and siRNAs are short RNAs synthesized within 
the cell or deriving from extracellular sources such as 
viruses and transposons, respectively. Two double-
stranded RNA filaments named sense and antisense 
strand constitute siRNAs and miRNAs. The antisense 
strand is incorporated into the protein complex RISC 
(RNA-induced silencing complex) guiding it to the RNA 
target. In the case of miRNAs, the antisense strand 
binds the target RNA via a partial complementarity; 
a perfect complementarity occurs in contrast for the 
siRNA antisense strand. miRNA-guided RISC induces 
the down-regulation of target gene expression either 
via the impairment of protein translation or via the 
degradation of the target RNA[8]. siRNA-guided RISC 
represses target gene expression only via target RNA 
degradation.
As it is possible to chemically generating siRNAs 
Molecular targets for HCC
Different strategies have been recently investigated 
to try to combat HCC (Table 1). Among these, it can 
be included approaches based on: (1) the targeting 
of proteins more relevant for HCC cell survival than 
for normal liver cells; (2) the targeting of genes 
overexpressed in HCC compared to the healthy liver; 
and (3) the targeting of genes causing drug resistance.
Within approach 1, the siRNA-mediated silencing 
of integrins should be mentioned. Integrins are 
extracellular matrix receptors playing important and 
different roles with regard to the regulation of cell 
motility, survival and proliferation. Bogorad et al[20] 
have used multiple anti-integrin siRNAs, chemically 
modified to improve the stability, to reduce the 
off-target potential and to minimize the possible 
immune response. As delivery device, nanoparticles 
made by ionisable lipid or cationic lipid were used to 
form spontaneous complexes with siRNAs. In vivo 
(rat model), short term (two weeks) targeting of 
integrins did not significantly alter liver functions, as 
evaluated by histological analysis and by checking 
the biochemical markers of liver function. However, 
long-term down-regulation (seven weeks) caused 
alterations in liver morphology. In HCC tissue, integrins 
targeting invariably down modulate HCC progression, 
via the reduction of cell proliferation and the increase 
of tumor cell death. These data indicate that HCC cells 
are more sensitive to integrins targeting than normal 
hepatocytes. This supports the concept that siRNA-
mediated inhibition of integrins may preferentially 
affect HCC tissue in so resulting in a specific effect. 
However, the observed negative effects to the healthy 
liver in the long-term suggests that a more refined 
delivery approach has to be developed for futures 
studies.
More common in the literature are works addressing 
the silencing of gene over-expressed in HCC compared 
to normal liver (approach 2). Clinicians know very well 
that a major problem in improving the survival of HCC 
patients is represented by the early recurrence of the 
disease. To study this aspect, Chen et al[21] explored 
the possibility of down regulating the Epithelial cell 
transforming sequence 2 (ECT2). Overexpression of 
ECT2 has been described in several human cancers 
including lung, oesophageal and glioblastoma. In 
HCC, the authors found that ECT2 is up-regulated in 
tumor samples compared to normal tissues. Moreover, 
ECT2 expression is markedly up-regulated in early 
recurrent HCC tissues compared to non-recurrent. 
Notably, patients with high ECT2 expression have a 
significantly shorter disease free duration compared to 
patients with low ECT2 expression. In a subcutaneous 
xenograft model of HCC, it was demonstrated that 
ECT2 targeting by siRNAs delivered via a viral vector, 
significantly reduced tumor growth. This was due 
to a G1 phase arrest secondary to the inhibition of 
the Rho/ERK pathway. Despite no reported evidence 
of improved animal survival, this work opens the 
possibility that ECT2 is an attractive target to reduce 
HCC recurrence.
Huang et al[22] have used an interesting approach to 
identify novel anti HCC target. The authors established 
a murine HCC model driven by Myc overexpression 
and p53 loss, two genetic signatures commonly found 
in human HCC. The authors screened in the HCC 
model developed a custom library of short hairpin 
RNAs (shRNAs) directed against known drug targets. 
By this approach, it was possible to identify Cdk9, a 
key component of the transcription elongation factor b 
complex. In vitro and in a murine orthotopic model of 
HCC, it was shown that the siRNA mediated silencing 
of CdK9 down modulates the aberrant proliferation of 
Myc-overexpressing HCC tumor. These data indicate 
CDK9 inhibition as a therapeutic strategy for Myc-
overexpressing liver tumors. No evidences of the 
effects of CdK9 targeting in the normal liver cells were 
reported, thus a possible toxicity for the normal liver 
cannot be excluded. Of course, this event may be 
circumvented by using delivery systems specifically 
targeting HCC cells but not normal hepatocytes.
To control viral infection, cells produce interferons 
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Figure 1  Small interfering RNAs/micro-interfering RNAs delivery. Ideally, 
the optimal delivery system should be able to discriminate between healthy 
hepatocytes (brown cells) and hepatocellular carcinoma cells (red cell). In 
addition, it should be able to protect small interfering RNAs (siRNAs)/micro-
interfering RNAs (miRNAs) and favor their cellular uptake. NPs: Nanoparticles 
loaded with the therapeutic siRNAs/miRNAs.
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negative impact on liver regeneration. This is a pivotal 
feature for any HCC therapeutic approach; indeed, 
liver carcinomas mostly arise in cirrhotic livers with 
impaired function and regenerative capacity, which 
should not be affected by the therapeutic approach. 
As the authors demonstrated the significant lack of 
toxicity following Mapk14 chemical inhibition alone, the 
same should be done also when using siRNAs.
Aurora kinases are a novel family of serine/
threonine kinases which includes Aurora-A, Aurora-B 
and Aurora-C. Aurora-A is crucial for mitosis and 
has a relevant role in tumorigenesis. In HCC the 
expression level of Aurora-A has been proposed as 
a reliable marker to predict HCC patient prognosis. 
Based on these observations, Zhang et al[25] studied 
the effects of Aurora-A silencing by siRNAs. In HCC 
cell lines, Aurora-A silencing significantly reduced 
colony formation and promoted apoptosis. Moreover, 
the down regulation of Aurora improved the chemo-
sensitivity to the chemotherapeutic agents adriamycin 
and cisplatin via the increase of apoptosis. These 
data were subsequently confirmed in a subcutaneous 
xenograft mouse model where it was shown that not 
only Aurora-A silencing reduced tumor growth but also 
potentiated the effects of adriamycin and cisplatin. 
Despite no evidences of improved animal survival have 
been reported and no investigations on the effects of 
Aurora-A silencing in healthy hepatocytes have been 
performed, this study may pave the way for a novel 
approach to HCC treatment.
Liver directed delivery systems for siRNAs/miRNAs
In addition of being effective, therapeutic approaches 
should be as specific as possible to avoid significant 
toxic effects. The works above discussed indicate 
that a certain level of specificity can be achieved by 
targeting gene products more relevant for HCC cell 
survival than normal liver cells. However, this level of 
specificity has to be improved, especially for drugs 
administered systemically. To this end, researchers 
have explored the possibility to develop liver specific 
delivery following various approaches (Table 2).
Sajeesh et al[26] developed nanoparticles (NPs) 
(IFNs), a series of pro-inflammatory cytokines, which 
can block viral infection and replication. IFNs exert 
their action via the activation of a number of effectors 
among which IFN-stimulated genes 15 (ISG15). This 
is an ubiquitin-like protein that conjugates to cellular 
substrates to form ISGylated proteins; the conjugation 
provides a tag that either marks the labeled protein 
for degradation or modulates its function. Aberrant 
functioning of ISG15 correlates with aberrant cell 
signaling and malignant transformation. Recently it 
has been shown[23] that ISG15 is highly expressed in 
HCC tissues and its expression significantly correlates 
with the HCC differentiation grade and patient survival. 
Based on these observations, in a subcutaneous 
xenograft mouse model of HCC, the authors 
administered by direct tumor injection, an anti ISG15 
siRNA. ISG15 silencing significantly inhibited tumor 
growth and reduced micro-vessel density. Notably, a 
prolonged animal survival of about 15% was observed. 
Whereas future investigation on the effects of ISG15 
targeting in healthy hepatocytes are required, the data 
reported constitute a first step in the identification of 
ISG15 as a valuable siRNA target to counteract HCC.
With regard to approach 3 (targeting of genes 
causing drug resistance), it should be mentioned the 
work of Rudalska et al[24]. The authors have proposed 
a strategy based on the identification of gene products 
whose inhibition can increase the therapeutic efficacy 
of the only approved anti HCC drug, i.e., sorafenib. 
It was thus developed a novel siRNA-based approach 
to screen in vivo genes whose inhibition increases 
the therapeutic efficacy of sorafenib. Because of 
this investigation, the kinase Mapk14 resulted to 
be a key element of sorafenib resistance in mouse 
and human liver cancer. The siRNA mediated intra-
tumor knockdown of Mapk14, sensitized the mice to 
sorafenib treatment resulting in a significant longer 
survival and reduced tumor growth compared to mice 
treated by sorafenib alone. Notably, Mapk14 inhibition 
did not result in a significant toxicity for the treated 
animals, as evaluated by body weight measurement. 
Moreover, the authors showed that the combinatorial 
treatment with sorafenib and Mapk14 inhibitor had no 
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Table 1  Targeting hepatocellular carcinoma related gene products
No. Approach Molecular target In vivo  model Effects Ref.
1 Targeting molecules more relevant for HCC 
than normal liver 
Integrins Mouse genetically induced HCC Reduction HCC cell proliferation 20
2 Targeting molecules overexpressed in HCC 
tissue 
ECT2 Mouse xenograft HCC Reduction HCC cell proliferation 21
3 Targeting molecules overexpressed in HCC 
tissue 
CDK9 Mouse orthotopic HCC Reduction HCC cell proliferation 22
4 Targeting molecules overexpressed in HCC 
tissue 
ISG15 Mouse xenograft HCC Reduction HCC cell proliferation 23
5 Targeting of genes causing drug resistance Mapk14 Mouse genetically induced HCC Increased sorafenib sensitivity 24
6 Targeting of genes causing drug resistance Aurora-A Mouse xenograft HCC Increased adriamycin and cisplatin 
sensitivity
25
HCC: Hepatocellular carcinoma.
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constituted by siRNAs bound to linear high molecular 
weight polyethyleneimine (PEI), functionalized with 
galactose (GAL) units. PEI, a polymer with repeating 
unit composed of amine, is able to condense nucleic 
acid molecules into positively charged particles, 
which in turn can bind to the anionic surface of 
cells allowing uptake via endocytosis. Galactose is 
a molecule recognized by the asialoglycoproteins 
receptors present on liver cells, thus facilitating a 
receptor-mediated uptake. In vitro, NPs containing 
GAL modified PEI complexed with Cy3 labeled siRNA, 
reached significantly better uptake in the liver Hep3B 
and Hepa 1-6 cells compared to NPs lacking GAL 
residues. Functional studies, performed using siRNAs 
targeted against the ApoB gene, showed a marked 
reduction in the target mRNA which was reduced down 
to 70% at the siRNA concentration of 100 nmol/L. NPs 
delivered systemically in mouse, showed the maximum 
accumulation in the liver region with a remarkable 
reduction in target mRNA which reached 40%. This 
interesting approach may represent a starting point 
to develop HCC specific delivery system; however, it 
has to be improved the ability to discriminate between 
healthy and tumor liver cells.
Recently we developed a novel polymeric-based 
delivery system for siRNAs in HCC cells. We used a 
copolymer based on α,β-poly(N-2-hydroxyethyl)-D,L-
aspartamide (PHEA) bearing positively chargeable side 
oligochains, with diethylamino ethyl methacrylate as 
monomer. In vitro, a siRNA against the transcription 
factor E2F1, was successfully delivered to the HCC 
cell line HuH7. Consequently, the successful E2F1 
targeting resulted in a significant decrease of HuH7 
proliferation, as expected due to the relevant role of 
E2F1 in HCC[27,28]. An advantage of our system is that it 
can effectively deliver not only siRNA but also plasmid 
DNA (pDNA). Thus, it allows minimizing possible 
artifacts introduced by the use of different delivery 
agents for siRNAs and pDNA. The possibility to employ 
the same delivery system is very convenient for many 
experimental settings where long (pDNA) and short 
(siRNA) needs to be delivered to same target cells. 
Potentially, our system can allow the co-delivery of 
a therapeutic siRNA together with a therapeutic long 
nucleic acid encoded by the plasmid. Future studies in 
animal models will better define the effectiveness of 
our copolymer (work in progress).
Another novel siRNA delivery-polymer we recently 
developed is based on inulin (Inu), an abundant and 
natural polysaccharide, conjugated with diethyle-
netriamine (DETA) residues (Inu-DETA)[29]. Our data 
indicate that Inu-DETA polyplexes can effectively 
bind siRNAs, are highly cyto-compatible and, in the 
hepatocellular carcinoma cells JHH6, can effectively 
deliver functional siRNA targeted against the mRNA of 
the cell promoter gene E2F1. This, in turn, induces a 
potent anti-proliferative effect. Notably, we observed 
that the mechanism of polymer-siRNA uptake and 
trafficking, i.e., micropinocytosis and clatrin mediated 
endocytosis, is crucial to allow the proper siRNA 
cellular distribution and thus effectiveness in JHH6. In 
contrast, in the bronchial cell line 16HBE where the 
uptake mechanism (caveolae mediated endocytosis) 
does not allow the proper distribution of siRNA within 
the cell, no significant effects are observed. This data 
stresses the relevance of the proper trafficking for 
efficient siRNA delivery and suggests that delivery 
specificity may be also achieved at the trafficking level. 
Future in vivo investigations will better define this 
peculiar feature of our delivery polymer.
Lipids are frequently used as siRNA delivery devices 
in many experimental therapeutic approaches[30] 
including those targeting the liver. Cationic lipids, 
bearing different degrees of positive charges, are the 
most studied system used for nucleic acid delivery. 
They can protect siRNAs from degradation and, due 
to the positive charge, can promote the binding to 
the negatively charged cell surface. Lipid NPs can be 
combined with polyethylene glycol (PEG), a polymer 
consisting of ethylene oxide able to stabilize lipid NPs. 
In addition, PEG can protect lipid NPs shielding them 
from inactivation by the immune system. Using lipid-
PEG carriers, Chen et al[31] studied the possibility 
to prepare liver directed NPs containing siRNAs via 
subcutaneous (sc) administration. The advantages of 
s.c. administration compared to iv include the potential 
for self-administration and a prolonged therapeutic 
window due to a depot effect. The authors investigated 
the effects of NPs size and the influence of hepatocyte-
specific targeting ligands. Variation in NP size was 
obtained by varying the PEG-lipid content. Optimal 
NPs size for liver accumulation was found to be of 
approximately 45 nm. These NPs allowed a reduction 
of the siRNA target (FVII mRNA) down to 80% of 
control. FVII, one of the proteins that causes blood 
to clot in the coagulation cascade, is produced and 
secreted by hepatocytes into the circulation. Notably, 
following a single sc injection with 1 mg/kg of NPs, 
the amount of circulating FVII was reduced down to 
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Table 2  Delivery systems for short RNAs
No. Approach Molecular 
target
In vivo  model Effects Ref.
1 PEI-GAL nano 
particles
ApoB Normal 
mouse liver
Healthy liver 
targeting
26
2 PHEA-
DEAEMA
E2F1 - HCC cell in 
vitro targeting
27
3 Inu-DETA E2F1 - HCC cell in 
vitro targeting
29
4 Lipid-PEG FVII Normal 
mouse liver
Healthy liver 
targeting
31
5 pH-sensitive 
lipids
miRNA 122 Normal 
mouse liver
Healthy liver 
targeting
32
6 US sensible 
lipids
BCL-2 Mouse 
Xenograft 
HCC
HCC 
targeting
33
PEI: Polyethyleneimine; DEAEMA: Diethylamino ethyl methacrylate; 
miRNA: Micro interfering RNA; HCC: Hepatocellular carcinoma.
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50% with the effect lasting up to seven days. Smaller 
particles (approximately 35 nm) were far less effective. 
However, the incorporation into these smaller NPs of 
galactose residues, dramatically improved the efficacy 
as almost 90% of FVII knockdown was obtained 
with the effect lasting for 7 d. These data confirm 
the usefulness of using liver targeting molecules and 
indicate the relevance of NPs physical properties such 
as the size.
Lipids have been also utilized to deliver nucleic 
acid molecules without conjugates; in this case, 
other smart modifications have been introduced. For 
example, Hatakeyama et al[32] developed lipid NPs 
(MEND) containing a pH-sensitive cationic lipid YSK05 
(YSK05-MEND). These NPs, being pH-sensitive, favor 
endosome escape and thus nucleic acid diffusion 
in the cytosol. The authors loaded NPs with a short 
nucleic acid (anti miRNA 122) targeting miRNA 122. 
This is a liver specific miRNA playing important roles 
in liver physiology (lipid metabolism) and HCC. The 
choice of targeting a liver specific miRNA, confers to 
the approach an intrinsic specificity. In cultured liver 
cancer cells (Hepa1c1c7), YSK05-MEND had improved 
delivery efficacy compared to the commercially 
available lipid Lipofectamine 2000 (LFN2k), mostly due 
to the efficient endosomal escape. Notably, significantly 
reduced toxicity was observed compared to LFN2k. In 
mouse, following vein tail administration, there was 
a predominant accumulation in the liver. The authors 
explained this observation with the fact that neutral 
liposomes tend to absorb apolipoprotein E (apoE) in 
the circulation; this in turn enhances the uptake of the 
liposomes by hepatocytes via specific receptors (low-
density lipoprotein receptors). In this regard, it would 
have been interesting to test whether the delivery 
system developed has the possibility to discriminate 
between healthy and cancer hepatocytes in vivo. 
The accumulation of NPs in the liver was paralleled 
by the knockdown of miR-122 with the increase of 
the mRNA levels of the miR-122 target genes. This 
effect lasted up to two weeks. Notably, no major 
toxicity was observed as evaluated by mouse body 
weight measurement over 25 d and by monitoring 
liver transaminases levels (48 h after NPs injection). 
This smart work indicates that liver targeting may be 
achieved also via physiological features such as the 
lipid absorption of apoE. 
Lipid NPs carrying nucleic acids can also be 
prepared to contain an ultrasound (US) gas. The 
application of a US pressures above a certain threshold 
causes a violent NPs collapse which results in NPs 
disruption and nucleic acid release. In vivo, US also 
determine the transient disruptions of cell membranes, 
thus allowing the transport of nucleic acid from NPs to 
cells. Applying US at a defined site, it is also possible 
obtaining a specific delivery via a physical approach. 
Yin et al[33] have used the US sensible NPs (US-NPs) 
to deliver a siRNA together with the anti-tumor drug 
paclitaxel (PTX). In the HCC cell line HepG2 in the 
presence of US, US-NPs loaded by a red fluorescent 
siRNA and a green vital die, could deliver efficiently 
the two molecules through the entire cells and to the 
cytoplasm, respectively. Notably, in the absence of 
US, the delivery efficiency was dramatically reduced. 
US-NPs loaded PTX and a siRNA against the mRNA 
of the anti-apoptotic gene BCL-2, resulted in the 
remarkable down regulation of BCL-2 in the presence 
of US. This in turn determined a potent pro-apoptotic 
effect significantly superior to those obtained by 
US-NPs loaded with PTX or siRNA alone. For in vivo 
studies, the authors used a mouse HepG2 xenograft 
subcutaneous model. Following die labelled US-NPs 
delivery via the tail vein, it was possible to observe 
a clear tumor localization of US-NPs only upon US 
application. Using US-NPs loaded by PTX and siRNA 
anti BCL-2, the application of US substantially blocked 
the tumor growth; this resulted in an increase of 
animal survival compared to all the controls considered 
(US-NPs with PTX and siRNA without US application, 
US-NPs with PTX and US application, US-NPs with 
siRNA and US application). This work is particularly 
interesting as it shows the possibility to get a target 
delivery via a physical approach. It remains to be 
determined how efficient the system could be in 
an orthotopic model of HCC. Despite this, the work 
demonstrates the possibility to overcome HCC drug 
resistance by combining clinically used drug and siRNA. 
CONCLUSION
Effective therapeutic approaches for HCC, especially 
in its advanced forms, are now not available. In this 
regard, the use of siRNAs/miRNAs is considered to 
have a great therapeutic potential. This is substantially 
because it is possible to generate siRNAs/miRNAs 
silencing the expression of any genes implicated 
in HCC. Additionally, by properly addressing the 
possible off targeting effect, it is feasible to reach 
a great specificity of biological action. The use of 
multiple siRNAs/miRNAs also allows to target different 
members of a pathological pathway, potentially 
resulting in an improved anti HCC effects. In addition, 
the combination of siRNAs/miRNAs administered with 
clinical used drugs may reciprocally potentiate the 
therapeutic effects of the two types of molecules. 
Despite the great therapeutic potential, the use of 
siRNAs/miRNAs as anti HCC agents has not yet reached 
the clinical relevance. This is substantially due to the 
lack of appropriate delivery systems. If administered 
as naked molecules, siRNAs/miRNAs are rapidly 
degraded by nucleases, cleared by the kidneys and 
cannot efficiently cross cellular membranes. Whereas 
these aspects can be significantly circumvented by 
the available delivery systems, further optimization 
is required for the targeting issue. Examples of 
liver directed delivery systems are described in the 
literature; however, improvements in the possibility to 
discriminate between HCC and normal liver cells is still 
8999 August 14, 2015|Volume 21|Issue 30|WJG|www.wjgnet.com
Farra R et al . Anti HCC siRNAs and miRNAs
necessary. Additionally, it should be considered that the 
HCC tissue is almost exclusively arterially vascularized, 
unlike the normal liver, which has a dual supply with 
a portal component of 75% to 80% and an arterial 
component of only 20% to 25%[34]. This implies that 
it will be important to concentrate the attention on the 
development of delivery systems suited for the intra-
arterial administration rather the iv.
In conclusion, despite further improvements in 
the use of siRNA/miRNAs as potential novel anti HCC 
drugs are necessary, the progresses achieved in the 
last years fully justify further efforts in the field.
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